To include your compound in the COVID-19 Resource Center, submit it here.

Zynerba discontinuing ZYN002 and ZYN001 for pain indications

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will discontinue development of ZYN002 to treat osteoarthritis (OA) pain and ZYN001 to treat fibromyalgia and

Read the full 220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE